Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled trial of toludesvenlafaxine hydrochloride extended-release tablets for generalized anxiety disorder
CTR20231959Phase 3Completed
- Sponsor
- Luye Pharma Group
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of toludesvenlafaxine in generalized anxiety disorder (GAD), sponsored by Luye Pharma Group. Started Jun 2023; status: completed.
02
Drugs
toludesvenlafaxine
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on CTR20231959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231959.